Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
08 Noviembre 2023 - 7:05AM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked
first for the second year in a row on the 2023 Deloitte Technology
Fast 500™, a list of the fastest-growing technology, media,
telecommunications, life sciences, fintech and energy tech
companies in North America. This is the first time in the 29-year
history of the Deloitte Technology Fast 500 program that a company
has topped the list for two consecutive years.
The Company’s revenue growth between fiscal years 2019 and 2022
was fueled by global sales of sotrovimab (Xevudy®), an
investigational SARS-CoV-2 neutralizing monoclonal antibody, and
was recognized in conjunction with Vir’s collaboration partner GSK,
as well as additional contract, licensing and grant agreements with
GSK and others, including Brii Biosciences and the Bill &
Melinda Gates Foundation.
“Ranking number one for the second year in a row on the Deloitte
Technology Fast 500 list reflects Vir’s ability to leverage our
world class immunology expertise to engineer human antibodies into
very powerful medicines,” said Marianne De Backer, M.Sc., Ph.D.,
MBA, Vir’s Chief Executive Officer. “This growth success is fueling
our clinical programs while also strengthening our scientific
platforms and pipeline so we can continue to power the immune
system to transform lives.”
About the 2023 Deloitte Technology Fast 500™
Now in its 29th year, the Deloitte Technology Fast 500 provides
a ranking of the fastest-growing technology, media,
telecommunications, life sciences, fintech, and energy tech
companies – both public and private – in North America. Technology
Fast 500 award winners are selected based on percentage fiscal year
revenue growth from 2019 to 2022.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company’s operating revenues. Companies must have base-year
operating revenues of at least US$50,000, and current-year
operating revenues of at least US$5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
About Sotrovimab
Sotrovimab is an investigational SARS-CoV-2 neutralizing
monoclonal antibody that was developed in collaboration with GSK.
The antibody binds to an epitope on SARS-CoV-2 shared with
SARS-CoV-1 (the virus that causes SARS). Sotrovimab, which
incorporates Xencor, Inc.’s Xtend™ technology, has been designed to
achieve high concentration in the lungs to achieve optimal
penetration into airway tissues affected by SARS-CoV-2 and to have
an extended half-life. Sotrovimab was identified using Vir’s
proprietary mAb discovery platform. Sotrovimab is currently not
authorized in the US.
About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on
combining cutting-edge technologies to treat and prevent infectious
diseases and other serious conditions. Vir has assembled two
technology platforms that are designed to stimulate and enhance the
immune system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding Vir’s
strategy, plans and prospects, Vir’s plans to rapidly advance a
pipeline aimed at serious infectious diseases and other serious
conditions, and its expectations regarding the timing of planned
data readouts from its hepatitis B and hepatitis delta viruses and
human immunodeficiency virus development programs. Many factors may
cause differences between current expectations and actual results,
including unexpected safety or efficacy data or results observed
during clinical trials or in data readouts; the occurrence of
adverse safety events; risks of unexpected costs, delays or other
unexpected hurdles; difficulties in collaborating with other
companies; successful development and/or commercialization of
alternative product candidates by Vir’s competitors; changes in
expected or existing competition; delays in or disruptions to Vir’s
business or clinical trials due to the COVID-19 pandemic,
geopolitical changes or other external factors; and unexpected
litigation or other disputes. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106932182/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1-314-368-5189
Investors Sasha Damouni Ellis Executive Vice President,
Chief Corporate Affairs Officer sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024